D-Street Buzz: Pharma stocks gain led by Sun Pharma; Titan spikes 4%, RIL most active

The Indian benchmark indices continued to hold steady with the Nifty50 jumping 100 points, trading at 10,879 while the Sensex zoomed 343 points and was trading at 36,148.

Nifty Pharma added over 1.5 percent led by gains from Sun Pharma which spiked close to 4 percent followed by Dr Reddy’s Labs, Piramal Enterprises and Cadila Healthcare.

From the media space, the top gainers were Network 18 which jumped 5 percent followed by Zee Entertainment, Sun TV Network, International EROS and DB Corp.

Midcap stocks were also buzzing led by NBCC, PAGE Industries, Power Finance, REC, Reliance Infra, Reliance Power, Apollo Tyres, Balkrishna Industries, Bharat Forge, Godrej Industries, JSPL, Jubilant Foodworks and Muthoot Finance among others.

The top gainers from NSE include Sun Pharma, Zee Entertainment, IOC, Titan Company and YES Bank while the top losers included Bharti Infratel, Coal India, Asian Paints, Bajaj Auto and Hero Moto.
The most active stocks were Reliance Industries, Titan Company, YES Bank, HDFC Bank and Sun Pharma.

Bata India, Commercial Engineers & Body Builders, Proseed India and SPL Industries have hit new 52-week high on NSE in this afternoon session.43 stocks have hit new 52-week low including names like Adhunik Metaliks, California Software, Mcnally Bharat Engineering, Ortel Communications, Shilpi Cable and Visesh Infotecnics among others.
The breadth of the market favoured the advances with 1151 stocks advancing and 520 declining while 392 remained unchanged. On the BSE, 1551 stocks advanced, 945 declined and 152 remained unchanged.

Disclosure: Reliance Industries Ltd. is the sole beneficiary of Independent Media Trust which controls Network18 Media & Investments Ltd.

  • Related Posts

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    New Delhi: Union Minister Dr Jitendra Singh on Saturday said that India is steadily evolving into a robust pharma economy, which could help as a significant contributor to the country’s…

    Unapproved drops for dry eyes pose risks: Govt

    NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    India advancing as a global hub of affordable, quality healthcare solutions: Dr Jitendra Singh

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Govt highlights multi-layer framework to curb misleading advertisements

    Govt highlights multi-layer framework to curb misleading advertisements

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal